2019 Symposium
|
2019 Featured Talks » Panel Discussion: Immuno OncologyPanel Discussion: Immuno Oncology
Chair: Sandip Patel, MD UC San Diego Moores Cancer Center Eric Ostertag, MD, PhD, Poseida Therapeutics Shabnam Shalapour, PhD, UC San Diego Travis Young, PhD, Calibr at Scripps Research Sandip Patel, MD Dr. Sandip Patel, MD is an Associate Professor at UCSD and a medical oncologist focused on early development of novel immunotherapy, in particular early phase clinical trials of cancer immunotherapy and thoracic oncology immunotherapy trials. His research focus is on predictive biomarkers for immunotherapeutic response and generation of personalized cancer immunotherapy regimens.
Eric Ostertag, MD, PhD Dr. Eric Ostertag is currently the Chief Executive Officer of Poseida Therapeutics, a clinical-stage company using proprietary non-viral gene engineering technologies to create CAR-T and other therapies in pursuit of a potential cure for a number of cancers, including multiple myeloma. Before starting Poseida, he founded and served as the Chief Executive Officer and President of Transposagen Biopharmaceuticals, Inc., a gene editing technology company focused on research reagents, and from which Poseida was spun out in 2015. Dr. Ostertag received both his Ph.D. in Molecular Biology and his M.D. from the University of Pennsylvania School of Medicine and his B.S. in Genetics from the University of Wisconsin-Madison. Shabnam Shalapour, PhD Dr. Shalapour is an assistant adjunct professor at UCSD Department of Pharmacology. She started her research career with a Diploma degree in Biochemistry from the Department of Biochemistry at the University of Duesseldorf (Germany). After completing her Diploma thesis, she shifted her focus to cancer research with an emphasis in immunology. She received her PhD under the supervision of Dr. Blankenstein, a leading cancer immunologist at the Institute of Immunology, in a collaboration with Dr. Henze, a clinician in the field of childhood acute lymphoblastic leukemia (ALL) treatments (ALL-BFM trial) at the Department of Pediatric Oncology/Hematology at the Charité-Medical University of Berlin. Her PhD thesis involved experiments studying the relationship between bone marrow (BM) stroma cells and acute lymphoblastic leukemia cells. Thereafter, she decided to continue her focus on tumor immunity and inflammation. She was awarded the German Research Foundation fellowship, and in August 2012, she joined the laboratory of Dr. Michael Karin at UCSD to study inflammation and cancer.
Travis Young, PhD Dr. Young is the Vice President of Biologics at Calibr, a division of Scripps Research. He received a BS in biochemistry from Boston College and a PhD in chemical biology from The Scripps Research Institute as an ARCS scholar. At Scripps, his work focused on the development of unnatural amino acid incorporation methodologies to improve the properties of therapeutic proteins. This work was foundational for the development of programs in the Calibr pipeline today, including a bispecific antibody for prostate cancer which will enter clinical trials next year. After receiving his PhD, he completed a postdoc at Harvard Medical School with an NIH fellowship, in the department of Biological Chemistry and Molecular Pharmacology with Dr. Christopher T Walsh.
|